People living with insulin-dependent diabetes have been waiting a long time for someone to do something to make it more affordable. It looks like that time may finally be arriving.
Doctors have been treating diabetes with insulin since 1922. A century later, about one in five of the 37 million Americans living with diabetes take this medication—a hormone that helps cells absorb sugar from the blood.
Civica Rx, a nonprofit that manufactures generic drugs, is trying to help solve this problem. It’s planning to produce generic insulin for no more than $30 for a month’s worth of the drug at a factory being built in Petersburg, Va. Eventually the drugmaker intends to sell all three of the most popular kinds of insulin, starting in 2024 with glargine.
Seeing reasons for optimism I’m excited about this initiative because it promises to increase access to all people who require insulin in the U.S., regardless of insurance status or where they buy medications. I’m also optimistic because of support from large insurers as Anthem ANTM, -2.73% and Blue Cross Blue Shield Association for this effort. It’s reassuring that Civica Rx’s leadership includes many people with decades of experience in the pharmaceutical industry and in health policy.First, there have been prior attempts to manufacture generic insulin in the U.S. None have succeeded.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
San Antonio voters pass $1.2B bond, first to invest in affordable housingHere are the final raw vote totals in the San Antonio bond election. Turnout was lower than expected at 7.6%, even with two state constitutional amendments on the ballot aimed at addressing property taxes.
続きを読む »
UST stablecoin struggles to maintain $1 parity amid crypto market turbulenceThe algorithmic stablecoin UST, which is part of the Terra crypto ecosystem, is struggling to maintain parity with the dollar following a Saturday market event.
続きを読む »
First Quarter of 2022 Sees Record $1 Billion Spent on LobbyingWhile the health industry dominated overall, the top spender of 2022's first quarter was the U.S. Chamber of Commerce.
続きを読む »
Tech Giants Lost More Than $1 Trillion in Value in the Last Three Trading DaysThe biggest names of the technology industry are becoming more affordable as investors take account of the latest U.S. central bank decision.
続きを読む »